Identification

Name
Methylene blue
Accession Number
DB09241
Type
Small Molecule
Groups
Approved, Investigational
Description

Methylene blue has been found to have many uses in medicine.

It has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. It has been used as well for treatment of methemoglobinemia and other conditions. Methylene blue could also be used as urinary tract antiseptic.

Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease.

Structure
Thumb
Synonyms
  • Basic Blue 9
  • C.I. basic blue 9
  • Lowacryl blue 9
  • Methylene blue
  • Methylene blue anhydrous
  • methylenium ceruleum
  • Methylthioninium chloride
External IDs
C.I. 52015 / CI 52015 / CI-52015 / NSC-617593 / TRX-0014 / TRX0014
Product Ingredients
IngredientUNIICASInChI Key
Methylene blue trihydrateT42P99266K7220-79-3XQAXGZLFSSPBMK-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylene Blue Inj 1%Liquid10 mgIntramuscular; IntravenousAllen & Hanburys A Glaxo Canada Ltd. Co.1979-12-311996-09-10Canada
Methylene Blue Inj 1% USPLiquid1 %IntravenousDavid Bull Laboratories (Pty) Ltd.1991-12-311999-08-10Canada
Methylene Blue Inj 10mg/ml USPLiquid10 mgIntravenousGlaxo Canada Inc1979-12-311996-09-10Canada
Methylene Blue InjectionSolution10 mgIntravenousTeligent Ou2016-02-19Not applicableCanada
Methylene Blue Injection USPLiquid10 mgIntravenousOmega Laboratories Ltd2001-03-11Not applicableCanada
Methylene Blue Injection USPSolution10 mgParenteralSandoz Canada Incorporated1989-12-31Not applicableCanada
Methylene Blue Injection USPSolution10 mgIntravenousAlveda Pharmaceuticals Inc2008-08-28Not applicableCanada
Methylene Blue Injection, USPSolution10 mgIntravenousMylan Pharmaceuticals1994-12-31Not applicableCanada
Methylene Blue Injection, USPLiquid1 %IntravenousHospira, Inc.1999-06-232010-03-24Canada
ProvayblueInjection5 mg/mLIntravenousAmerican Regent2016-04-08Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylthioninium Chloride ProveblueInjection, solution5 mg/mlIntravenousProvepharm Sas2011-05-06Not applicableEu
Methylthioninium Chloride ProveblueInjection, solution5 mg/mlIntravenousProvepharm Sas2011-05-06Not applicableEu
Methylthioninium Chloride ProveblueInjection, solution5 mg/mlIntravenousProvepharm Sas2011-05-06Not applicableEu
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylene Bleu Liq 1%Liquid1 %OralLaboratoire Atlas Inc1951-12-31Not applicableCanada
Methylene Bleu Liq 2%Liquid2 %OralLaboratoire Atlas Inc1951-12-31Not applicableCanada
Methylene Blue Solution 1%Liquid1 %Oral; TopicalRougier Pharma Division Of Ratiopharm Inc1981-12-312015-10-01Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methylene BlueInjection, solution10 mg/mLIntravenousAmerican Regent1990-09-302017-07-20Us
Methylene BlueInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2010-12-172017-01-20Us
Methylene BlueInjection, solution10 mg/mLIntravenousAmerican Regent1990-09-302017-07-20Us
Methylene BlueInjection, solution10 mg/mLIntravenousGeneral Injectables & Vaccines2010-04-01Not applicableUs
Methylene BlueInjection, solution10 mg/mLIntravenousAmerican Regent1990-09-302017-07-20Us
Methylene BlueInjection10 mg/mLIntravenousAkorn2009-04-01Not applicableUs
Methylene BlueInjection, solution10 mg/mLIntravenousAmerican Regent1990-09-302017-07-20Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Azuphen MbMethylene blue (10 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Phenyl salicylate (36 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282018-01-06Us
Blue CollyriumMethylene blue (0.2 mg) + Naphazoline hydrochloride (0.5 mg)LiquidOphthalmicSandoz Canada Incorporated1997-05-13Not applicableCanada
Collyre BleuMethylene blue (0.2 mg) + Naphazoline hydrochloride (0.5 mg)Solution / dropsOphthalmicSabex Inc1991-12-311997-11-26Canada
Collyre Bleu LaiterMethylene blue (0.2 mg) + Naphazoline nitrate (0.5 mg)Solution / dropsOphthalmicBiocodex Sa1986-12-31Not applicableCanada
Eau Resolutive SokerMethylene blue (.1365 mg) + Camphor (.715 mg) + Cupric sulfate (28.925 mg) + Resorcinol (58.565 mg) + Zinc sulfate (88.4 mg)LiquidTopicalProduits Francais Labs Inc.1930-12-311997-05-30Canada
Hyolev MbMethylene blue (10.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81 mg/1) + Phenyl salicylate (32.4 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)TabletOralBurel Pharmaceuticals, Llc2015-06-262018-01-06Us
HyophenMethylene blue (10.8 mg/1) + Benzoic Acid (9 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81.6 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralStar Pharmaceuticals, Llc2010-09-21Not applicableUs00076 0901 01 nlmimage10 cc15e64f
Indiomin MbMethylene blue (10 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-28Not applicableUs
Me NaPhos MB Hyo 1Methylene blue (10.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81.6 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)TabletOralMethod Pharmaceuticals2015-12-01Not applicableUs
PhosphasalMethylene blue (10.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (81.6 mg/1) + Phenyl salicylate (36.2 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)TabletOralStar Pharmaceuticals, Llc2010-09-21Not applicableUs
Categories
UNII
8NAP7826UB
CAS number
61-73-4
Weight
Average: 319.85
Monoisotopic: 319.0909965
Chemical Formula
C16H18ClN3S
InChI Key
CXKWCBBOMKCUKX-UHFFFAOYSA-M
InChI
InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1
IUPAC Name
3,7-bis(dimethylamino)-5λ⁴-phenothiazin-5-ylium chloride
SMILES
[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1

Pharmacology

Indication

Methylene blue has several indications in medicine: 1. found to improve the hypotension associated with various clinical states. 2. Antiseptic in urinary tract infections. 3. Improves hypoxia and hyper dynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome. 4. Results in transient and reproducible improvement in blood pressure and cardiac function in septic shock. 5. Investigated for the treatment of Alzheimer's disease. 6. Treatment of ifofosamide induced neurotoxicity.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
  • Main mechanism of action involves inhibition of nitric oxide synthase and guanylate cyclase.
  • In Alzheimer: a mechanistic study found that methylene blue oxidizes cysteine sulfhydryl groups on tau to keep tau monomeric. One preclinical treatment study in tauopathy mice reported anti-inflammatory or neuroprotective effects mediated by the Nrf2/antioxidant response element (ARE); another reported insoluble tau reduction and a learning and memory benefit when given early.
  • In Methemoglobinemia: Methylene Blue acts by reacting within RBC to form leukomethylene blue, which is a reducing agent of oxidized hemoglobin converting the ferric ion (fe+++) back to its oxygen carrying ferrous state(fe++).
  • As antimalarial agent: Methylene Blue, a specific inhibitor of P.falciparum glutathione reductase has the potential to reverse CQ resistance and it prevents the polymerization of haem into haemozoin similar to 4-amino-quinoline antimalarials.
  • For ifofosamide induced neurotoxicity: Methylene blue acts as an alternative electron acceptor, and reverses the NADH inhibition of hepatic gluconeogenesis while also inhibiting the transformation of chloroethylamine into Chloroacetaldehyde, and also inhibits multiple amine oxidase activities, preventing the formation of Chloroacetaldehyde.
TargetActionsOrganism
AGuanylate cyclase soluble subunit alpha-2
antagonist
Human
ANitric oxide synthase, brain
antagonist
Human
Absorption
Not Available
Volume of distribution

10 mg/kg (in rats).

Protein binding

Methylene blue was reported to bind strongly to rabbit plasma (71–77% of bound drug).

Metabolism

Following distribution into tissues, rapidly reduced to leukomethylene blue (leucomethylthioninium chloride). Metabolism to leucomethylene blue may be less efficient in neonates than in older individuals.

Route of elimination

Excreted in urine and bile. About 75% of an oral dose excreted in urine, primarily as stabilized colorless leukomethylene blue.

Half life

5–6.5 hours (after IV dose).

Clearance

3.0 ± 0.7 L/min.

Toxicity

LD50 = 1180 mg/kg ( Rat ).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredRisk of severe hemolytic anemia or paradoxical methemoglobinemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Methylene blue.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Methylene blue.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Methylene blue.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Methylene blue.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Methylene blue can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Methylene blue.Experimental
AcebutololMethylene blue may increase the hypotensive activities of Acebutolol.Approved
AlaproclateAlaproclate may increase the serotonergic activities of Methylene blue.Experimental
AlfentanilMethylene blue may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlmasilateAlmasilate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Methylene blue.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolMethylene blue may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMethylene blue may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololMethylene blue may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmineptineAmineptine may increase the serotonergic activities of Methylene blue.Illicit, Withdrawn
AmitriptylineAmitriptyline may increase the serotonergic activities of Methylene blue.Approved
AmodiaquineThe serum concentration of Methylene blue can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the serotonergic activities of Methylene blue.Approved
AmphetamineAmphetamine may increase the serotonergic activities of Methylene blue.Approved, Illicit
ArotinololMethylene blue may increase the hypotensive activities of Arotinolol.Investigational
ArtemetherThe serum concentration of Methylene blue can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Methylene blue can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Methylene blue can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Methylene blue can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Methylene blue can be increased when it is combined with Artesunate.Approved, Investigational
AtenololMethylene blue may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Methylene blue can be increased when it is combined with Atovaquone.Approved
BefunololMethylene blue may increase the hypotensive activities of Befunolol.Experimental
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Methylene blue.Approved, Illicit
BetaxololMethylene blue may increase the hypotensive activities of Betaxolol.Approved
BevantololMethylene blue may increase the hypotensive activities of Bevantolol.Approved
BezitramideMethylene blue may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololMethylene blue may increase the hypotensive activities of Bisoprolol.Approved
BopindololMethylene blue may increase the hypotensive activities of Bopindolol.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Methylene blue.Experimental
BucindololMethylene blue may increase the hypotensive activities of Bucindolol.Investigational
BufuralolMethylene blue may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololMethylene blue may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineMethylene blue may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Methylene blue.Approved, Investigational
ButorphanolMethylene blue may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarfentanilMethylene blue may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CarteololMethylene blue may increase the hypotensive activities of Carteolol.Approved
CarvedilolMethylene blue may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololMethylene blue may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe serum concentration of Methylene blue can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Methylene blue.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Methylene blue can be increased when it is combined with Chlorproguanil.Investigational
CitalopramCitalopram may increase the serotonergic activities of Methylene blue.Approved
ClomipramineClomipramine may increase the serotonergic activities of Methylene blue.Approved, Vet Approved
CloranololMethylene blue may increase the hypotensive activities of Cloranolol.Experimental
CodeineMethylene blue may increase the hypotensive activities of Codeine.Approved, Illicit
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Methylene blue.Approved
Cycloguanil embonateThe serum concentration of Methylene blue can be increased when it is combined with Cycloguanil embonate.Experimental
DapoxetineDapoxetine may increase the serotonergic activities of Methylene blue.Investigational
DapsoneThe serum concentration of Methylene blue can be increased when it is combined with Dapsone.Approved, Investigational
DesipramineDesipramine may increase the serotonergic activities of Methylene blue.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Methylene blue.Approved
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Methylene blue.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Methylene blue.Approved
DextromoramideMethylene blue may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMethylene blue may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineMethylene blue may increase the hypotensive activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the serotonergic activities of Methylene blue.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Methylene blue.Approved, Illicit
DihydrocodeineMethylene blue may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMethylene blue may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMethylene blue may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiphenoxylateMethylene blue may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DosulepinDosulepin may increase the serotonergic activities of Methylene blue.Approved
DoxepinDoxepin may increase the serotonergic activities of Methylene blue.Approved
DoxycyclineThe serum concentration of Methylene blue can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEMethylene blue may increase the hypotensive activities of DPDPE.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methylene blue.Experimental, Illicit
DuloxetineDuloxetine may increase the serotonergic activities of Methylene blue.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methylene blue.Experimental, Illicit
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Methylene blue.Approved, Investigational
EpanololMethylene blue may increase the hypotensive activities of Epanolol.Experimental
EscitalopramEscitalopram may increase the serotonergic activities of Methylene blue.Approved, Investigational
EsmirtazapineEsmirtazapine may increase the serotonergic activities of Methylene blue.Investigational
EsmololMethylene blue may increase the hypotensive activities of Esmolol.Approved
EthylmorphineMethylene blue may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtoperidoneEtoperidone may increase the serotonergic activities of Methylene blue.Withdrawn
EtorphineMethylene blue may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FenfluramineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylMethylene blue may increase the hypotensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineFluoxetine may increase the serotonergic activities of Methylene blue.Approved, Vet Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Methylene blue.Approved, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Methylene blue.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Methylene blue.Experimental
HalofantrineThe serum concentration of Methylene blue can be increased when it is combined with Halofantrine.Approved
HarmalineHarmaline may increase the serotonergic activities of Methylene blue.Experimental
HeroinMethylene blue may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HydrocodoneMethylene blue may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphoneMethylene blue may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Methylene blue.Approved
HydroxychloroquineThe serum concentration of Methylene blue can be increased when it is combined with Hydroxychloroquine.Approved
ImipramineImipramine may increase the serotonergic activities of Methylene blue.Approved
IndalpineIndalpine may increase the serotonergic activities of Methylene blue.Investigational, Withdrawn
IndenololMethylene blue may increase the hypotensive activities of Indenolol.Withdrawn
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Methylene blue.Approved
IprindoleIprindole may increase the serotonergic activities of Methylene blue.Experimental
IproniazidIproniazid may increase the serotonergic activities of Methylene blue.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Methylene blue.Approved
KetobemidoneMethylene blue may increase the hypotensive activities of Ketobemidone.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Methylene blue.Approved, Nutraceutical, Withdrawn
LabetalolMethylene blue may increase the hypotensive activities of Labetalol.Approved
LandiololMethylene blue may increase the hypotensive activities of Landiolol.Investigational
LevobunololMethylene blue may increase the hypotensive activities of Levobunolol.Approved
Levomethadyl AcetateMethylene blue may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Methylene blue.Approved
LevorphanolMethylene blue may increase the hypotensive activities of Levorphanol.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Methylene blue.Approved, Investigational
LofentanilMethylene blue may increase the hypotensive activities of Lofentanil.Illicit
LofepramineLofepramine may increase the serotonergic activities of Methylene blue.Experimental
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Methylene blue.Approved
LumefantrineThe serum concentration of Methylene blue can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the serotonergic activities of Methylene blue.Approved
MefloquineThe serum concentration of Methylene blue can be increased when it is combined with Mefloquine.Approved
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Methylene blue.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methylene blue.Approved
MepindololMethylene blue may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolMethylene blue may increase the hypotensive activities of Meptazinol.Experimental
MethadoneMethylene blue may increase the hypotensive activities of Methadone.Approved
Methadyl AcetateMethylene blue may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Methylene blue.Approved, Illicit
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Methylene blue.Experimental
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methylene blue.Experimental
MetipranololMethylene blue may increase the hypotensive activities of Metipranolol.Approved
MetoprololMethylene blue may increase the hypotensive activities of Metoprolol.Approved, Investigational
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Methylene blue.Experimental, Illicit, Investigational
MilnacipranMilnacipran may increase the serotonergic activities of Methylene blue.Approved
MinaprineMinaprine may increase the serotonergic activities of Methylene blue.Approved
MirtazapineMirtazapine may increase the serotonergic activities of Methylene blue.Approved
MizoribineThe serum concentration of Methylene blue can be increased when it is combined with Mizoribine.Investigational
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Methylene blue.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Methylene blue.Approved
MorphineMethylene blue may increase the hypotensive activities of Morphine.Approved, Investigational
NadololMethylene blue may increase the hypotensive activities of Nadolol.Approved
NalbuphineMethylene blue may increase the hypotensive activities of Nalbuphine.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Methylene blue.Approved, Investigational
NebivololMethylene blue may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Methylene blue.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Methylene blue.Withdrawn
NicomorphineMethylene blue may increase the hypotensive activities of Nicomorphine.Experimental
NormethadoneMethylene blue may increase the hypotensive activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the serotonergic activities of Methylene blue.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine.Approved, Investigational
OpipramolOpipramol may increase the serotonergic activities of Methylene blue.Investigational
OpiumMethylene blue may increase the hypotensive activities of Opium.Approved, Illicit
OxprenololMethylene blue may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneMethylene blue may increase the hypotensive activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMethylene blue may increase the hypotensive activities of Oxymorphone.Approved, Investigational, Vet Approved
PargylinePargyline may increase the serotonergic activities of Methylene blue.Approved
ParoxetineParoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
PenbutololMethylene blue may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineMethylene blue may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PethidineMethylene blue may increase the hypotensive activities of Pethidine.Approved
PhenazocineMethylene blue may increase the hypotensive activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Methylene blue.Approved
PhenoperidineMethylene blue may increase the hypotensive activities of Phenoperidine.Experimental
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Methylene blue.Approved, Illicit
PindololMethylene blue may increase the hypotensive activities of Pindolol.Approved
PiperaquineThe serum concentration of Methylene blue can be increased when it is combined with Piperaquine.Approved, Investigational
PiritramideMethylene blue may increase the hypotensive activities of Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Methylene blue.Approved
Platelet Activating FactorMethylene blue may increase the hypotensive activities of Platelet Activating Factor.Experimental
PractololMethylene blue may increase the hypotensive activities of Practolol.Approved
PrimaquineThe serum concentration of Methylene blue can be increased when it is combined with Primaquine.Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Methylene blue.Approved
ProguanilThe serum concentration of Methylene blue can be increased when it is combined with Proguanil.Approved
PropranololMethylene blue may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the serotonergic activities of Methylene blue.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Methylene blue.Approved
PyrimethamineThe serum concentration of Methylene blue can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Methylene blue can be increased when it is combined with Pyronaridine.Investigational
QuinacrineThe serum concentration of Methylene blue can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Methylene blue can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Methylene blue can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of Methylene blue can be increased when it is combined with Radicicol.Experimental
RasagilineRasagiline may increase the serotonergic activities of Methylene blue.Approved
RemifentanilMethylene blue may increase the hypotensive activities of Remifentanil.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Methylene blue.Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Methylene blue.Approved
SelegilineSelegiline may increase the serotonergic activities of Methylene blue.Approved, Investigational, Vet Approved
SertralineSertraline may increase the serotonergic activities of Methylene blue.Approved
SinefunginThe serum concentration of Methylene blue can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolMethylene blue may increase the hypotensive activities of Sotalol.Approved
SufentanilMethylene blue may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Methylene blue can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Methylene blue can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Methylene blue.Approved, Investigational
TafenoquineThe serum concentration of Methylene blue can be increased when it is combined with Tafenoquine.Investigational
TalinololMethylene blue may increase the hypotensive activities of Talinolol.Investigational
TapentadolMethylene blue may increase the hypotensive activities of Tapentadol.Approved
TertatololMethylene blue may increase the hypotensive activities of Tertatolol.Experimental
ThiopentalThe risk or severity of adverse effects can be increased when Methylene blue is combined with Thiopental.Approved, Vet Approved
TianeptineTianeptine may increase the serotonergic activities of Methylene blue.Approved, Investigational
TilidineMethylene blue may increase the hypotensive activities of Tilidine.Experimental
TimololMethylene blue may increase the hypotensive activities of Timolol.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Methylene blue.Approved
TramadolMethylene blue may increase the hypotensive activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Methylene blue.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Methylene blue.Approved
TrazodoneTrazodone may increase the serotonergic activities of Methylene blue.Approved, Investigational
TrimethoprimThe serum concentration of Methylene blue can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the serotonergic activities of Methylene blue.Approved
TromethamineTromethamine can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Methylene blue.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Methylene blue is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Methylene blue is combined with Vortioxetine.Approved
ZimelidineZimelidine may increase the serotonergic activities of Methylene blue.Withdrawn
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Methylene blue.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kucukarslan N, Gunay C, Demirkilic U, Tatar H: Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg. 2005 May;79(5):1615-9. [PubMed:15854942]
  2. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD: Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995 Mar;80(3):473-9. [PubMed:7864410]
  3. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer RH, Kouyate B, Muller O: Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J. 2006 Oct 8;5:84. [PubMed:17026773]
  4. Boylston M, Beer D: Methemoglobinemia: a case study. Crit Care Nurse. 2002 Aug;22(4):50-5. [PubMed:12166056]
  5. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000 Jan;82(2):291-4. [PubMed:10646879]
  6. product info [Link]
  7. Article\ [Link]
  8. article [Link]
  9. Drug info [Link]
  10. Monograph [Link]
  11. msds [Link]
External Links
KEGG Compound
C00220
PubChem Compound
6099
PubChem Substance
310265144
ChemSpider
5874
ChEBI
6872
ChEMBL
CHEMBL405110
Wikipedia
Methylthioninium_chloride
ATC Codes
V03AB17 — Methylthioninium chlorideV04CG05 — Methylthioninium chloride
AHFS Codes
  • 92:12.00 — Antidotes
  • 36:36.00 — Gastric Function
  • 92:00.00 — Miscellaneous Therapeutic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCongenital methaemoglobinaemia / Methaemoglobinaemia1
1CompletedTreatmentG6PD Deficient / G6PD Normal / Healthy Volunteers1
1RecruitingTreatmentAbscesses1
1TerminatedTreatmentSepsis1
2Active Not RecruitingTreatmentAD / Aging / Alzheimer's Disease (AD) / MCI / Mild Cognitive Impairment (MCI)1
2CompletedNot AvailableBrain Activity1
2CompletedDiagnosticCancer, Breast1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentDementia, Alzheimer Type1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2CompletedTreatmentPlasmodium Infections2
2RecruitingTreatmentPeriradicular Disease1
2TerminatedSupportive CareLymphedema of the extremities / Recurrent Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer1
3CompletedTreatmentBipolar Disorder (BD)1
3Not Yet RecruitingTreatmentDysuria1
3RecruitingDiagnosticLiver Diseases1
3RecruitingTreatmentRefractory Shock / Shock, Septic1
3RecruitingTreatmentSevere Sepsis / Shock, Septic1
4Not Yet RecruitingSupportive CareSepsis1
4Not Yet RecruitingTreatmentAcquired Methaemoglobinaemia1
4RecruitingSupportive CareLiver Cirrhosis / Refractory Shock / Shock, Septic / Vasoplegia1
4TerminatedPreventionSecretion Removal Above ETT Cuff1
Not AvailableCompletedNot AvailableHyperparathyroidism1
Not AvailableCompletedBasic ScienceChronic Periodontitis1
Not AvailableCompletedDiagnosticMelanoma / Sentinel Node1
Not AvailableCompletedPreventionRespiratory Aspiration1
Not AvailableCompletedTreatmentInfiltrative Breast Cancer1
Not AvailableCompletedTreatmentLaparoscopy / Methylene Blue / Tubal Patency1
Not AvailableCompletedTreatmentPain, Neuropathic1
Not AvailableEnrolling by InvitationDiagnosticEarly Gastric Cancer / Malignant Neoplasm of Stomach / Sentinel Lymph Node1
Not AvailableEnrolling by InvitationTreatmentCancer, Breast / Sentinel Lymph Node1
Not AvailableRecruitingOtherBile Duct Injury1
Not AvailableTerminatedDiagnosticAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Stage I Cervical Cancer1
Not AvailableWithdrawnTreatmentSepsis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOphthalmic
Solution / dropsOphthalmic
LiquidTopical
LiquidOral1 %
LiquidOral2 %
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
LiquidIntramuscular; Intravenous10 mg
LiquidIntravenous1 %
LiquidIntravenous10 mg
SolutionIntravenous10 mg
SolutionParenteral10 mg
LiquidOral; Topical1 %
Injection, solutionIntravenous5 mg/ml
InjectionIntravenous5 mg/mL
CapsuleOral
Tablet, coatedOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)100 to 110 °C (with decomposition)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0296 mg/mLALOGPS
logP3.61ALOGPS
logP2.61ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)2.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity86.98 m3·mol-1ChemAxon
Polarizability33.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Dialkylarylamines / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organic chloride salts / Hydrocarbon derivatives
Substituents
Benzothiazine / Dialkylarylamine / Tertiary aliphatic/aromatic amine / Benzenoid / Heteroaromatic compound / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic chloride salt (CHEBI:6872)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Heme binding
Specific Function
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name
GUCY1A2
Uniprot ID
P33402
Uniprot Name
Guanylate cyclase soluble subunit alpha-2
Molecular Weight
81749.185 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. P...
Gene Name
NOS1
Uniprot ID
P29475
Uniprot Name
Nitric oxide synthase, brain
Molecular Weight
160969.095 Da

Drug created on October 23, 2015 14:18 / Updated on January 23, 2018 12:21